Menu
GWAS Study

Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers.

Ziliak D, O'Donnell PH, Im HK et al.

21497773 PubMed ID
GWAS Study Type
239 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

ZD
Ziliak D
OP
O'Donnell PH
IH
Im HK
GE
Gamazon ER
CP
Chen P
DS
Delaney S
SS
Shukla S
DS
Das S
CN
Cox NJ
VE
Vokes EE
CE
Cohen EE
DM
Dolan ME
HR
Huang RS
Chapter II

Abstract

Summary of the research findings

Identifying patients prior to treatment who are more likely to benefit from chemotherapeutic agents or more likely to experience adverse events is an aim of personalized medicine. Pharmacogenomics offers a potential means of achieving this goal through the discovery of predictive germline genetic biomarkers. When applied particularly to the treatment of head and neck cancers, such information could offer significant benefit to patients as a means of potentially reducing morbidity associated with platinum-based chemotherapy. We developed a genome-wide, cell-based approach to identify single nucleotide polymorphisms (SNPs) associated with platinum susceptibility and then evaluated these SNPs as predictors for response and toxicity in head and neck cancer patients treated with platinum-based therapy as part of a phase II clinical trial. Sixty head and neck cancer patients were evaluated. Of 45 genome-wide SNPs examined, we found that 2 SNPs, rs6870861 (P=0.004; false discovery rate [FDR] <0.05) and rs2551038 (P=0.005; FDR <0.05), were associated significantly with overall response to carboplatin-based induction chemotherapy when incorporated into a model along with total carboplatin exposure. Interestingly, these 2 SNPs are associated strongly with the baseline expression of >20 genes (all P ≤10(-4)), and that 2 genes (SLC22A5 and SLCO4C1) are important organic cation/anion transporters known to affect platinum uptake and clearance. Several other SNPs were associated nominally with carboplatin-related hematologic toxicities. These findings demonstrate importantly that a genome-wide, cell-based model can identify novel germline genetic biomarkers of platinum susceptibility, which are replicable in a clinical setting with treated cancer patients and seem clinically meaningful for potentially enabling future personalization of care in such patients.

90 East Asian ancestry lymphoblastoid cell lines

Chapter III

Study Statistics

Key metrics and study information

239
Total Participants
GWAS
Study Type
Yes
Replicated
90 European ancestry lymphoblastoid cell lines, 59 Yoruban ancestry lymphoblastoid cell lines
Replication Participants
European, Sub-Saharan African, East Asian
Ancestry
U.S., Nigeria, Niger, China, Japan
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.